PhAc-ALGP-Dox, a Novel Anticancer Prodrug with Targeted Activation and Improved Therapeutic Index

Abstract Clinical use of doxorubicin (Dox) is limited by cumulative myelo- and cardiotoxicity. This research focuses on the detailed characterization of PhAc-ALGP-Dox, a targeted tetrapeptide prodrug with a unique dual-step activation mechanism, designed to circumvent Dox-related toxicities and is ready for upcoming clinical investigation. Coupling Dox to a phosphonoacetyl (PhAc)-capped tetrapeptide forms the cell-impermeable, inactive compound, PhAc-ALGP-Dox. After extracellular cleavage by tumor-enriched thimet oligopeptidase-1 (THOP1), a cell-permeable but still biologically inactive dipeptide-conjugate is formed (GP-Dox), which is further processed intracellularly to Dox by fibroblast activation protein-alpha (FAPα) and/or dipeptidyl peptidase-4 (DPP4). In vitro, PhAc-ALGP-Dox is effective in various 2D- and 3D-cancer models, while showing improved safety toward normal epithelium, hematopoietic progenitors, and cardiomyocytes. In vivo, these results translate into a 10-fold higher tolerability and 5-fold greater retention of Dox in the tumor microenvironment compared with the parental drug. PhAc-ALGP-Dox demonstrates 63% to 96% tumor growth inhibition in preclinical models, an 8-fold improvement in efficacy in patient-derived xenograft (PDX) models, and reduced metastatic burden in a murine model of experimental lung metastasis, improving survival by 30%. The current findings highlight the potential clinical benefit of PhAc-ALGP-Dox, a targeted drug-conjugate with broad applicability, favorable tissue biodistribution, significantly improved tolerability, and tumor growth inhibition at primary and metastatic sites in numerous solid tumor models.

• Publication year

  2022

• Venue

  Molecular Cancer Therapeutics

• Publication date

  2022-02-11

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1158/1535-7163.MCT-21-0518PMID 35149549PMCID 9377749
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The Role of Extracellular Proteases in Tumor Progression and the Development of Innovative Metal Ion Chelators That Inhibit Their Activity

  2020cited by this paper
• Three-Dimensional Spheroids as In Vitro Preclinical Models for Cancer Research

  2020cited by this paper
• Thimet Oligopeptidase Biochemical and Biological Significances: Past, Present, and Future Directions

  2020cited by this paper
• Antibody–Drug Conjugates: The Last Decade

  2020cited by this paper
• Complex roles of cAMP–PKA–CREB signaling in cancer

  2020cited by this paper
• Thimet Oligopeptidase (EC 3.4.24.15) Key Functions Suggested by Knockout Mice Phenotype Characterization

  2019cited by this paper
• Identification of Prognostic and Metastatic Alternative Splicing Signatures in Kidney Renal Clear Cell Carcinoma

  2019cited by this paper
• Prognosis related miRNAs, DNA methylation, and epigenetic interactions in lung adenocarcinoma.

  2019cited by this paper
• In Vivo Antitumoral Efficacy of PhAc-ALGP-Doxorubicin, an Enzyme-Activated Doxorubicin Prodrug, in Patient-Derived Soft Tissue Sarcoma Xenograft Models

  2017influential reference
• Dexrazoxane added to doxorubicin-based adjuvant chemotherapy of breast cancer: a retrospective cohort study with a comparative analysis of toxicity and survival

  2017cited by this paper
• Tissue-protective activity of selenomethionine and D-panthetine in B16 melanoma-bearing mice under doxorubicin treatment is not connected with their ROS scavenging potential

  2017cited by this paper
• First-in-man phase I study assessing the safety and pharmacokinetics of a 1-hour intravenous infusion of the doxorubicin prodrug DTS-201 every 3 weeks in patients with advanced or metastatic solid tumours.

  2017cited by this paper
• A Review of Systemic Treatment in Metastatic Triple-Negative Breast Cancer

  2016cited by this paper
• Tissue-based map of the human proteome

  2015cited by this paper
• Expression of THOP1 and Its Relationship to Prognosis in Non-Small Cell Lung Cancer

  2014influential reference
• Analysis of tumor- and stroma-supplied proteolytic networks reveals a brain metastasis-promoting role for cathepsin S

  2014cited by this paper
• Targeting protein kinase A in cancer therapy: an update

  2014cited by this paper
• Expression Analysis of THOP1 in Background Liver, a Prognostic Predictive Factor in Hepatocellular Carcinoma, Extracted by Multiarray Analysis

  2014cited by this paper
• 14-3-3ε functions as an oncogene in SGC7901 gastric cancer cells through involvement of cyclin E and p27kip1.

  2014cited by this paper
• Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial.

  2014cited by this paper
• Extracellular Thimet Oligopeptidase is Carried by Cell Membrane Microvesicles of Human Prostate Cancer Cells

  2013cited by this paper
• The opposite effects of doxorubicin on bone marrow stem cells versus breast cancer stem cells depend on glucosylceramide synthase.

  2012cited by this paper
• A Direct Measurement of the Radiation Sensitivity of Normal Mouse Bone Marrow Cells1

  2012cited by this paper
• Natural intracellular peptides can modulate the interactions of mouse brain proteins and thimet oligopeptidase with 14‐3‐3ε and calmodulin

  2012cited by this paper
• Concise Review: Neutral Endopeptidase (CD10): A Multifaceted Environment Actor in Stem Cells, Physiological Mechanisms, and Cancer

  2011cited by this paper
• Overexpression of 14‐3‐3ε predicts tumour metastasis and poor survival in hepatocellular carcinoma

  2011cited by this paper
• A direct measurement of the radiation sensitivity of normal mouse bone marrow cells. 1961.

  2011cited by this paper
• Proteolytic networks in cancer.

  2011cited by this paper
• Selective cytotoxic activities of two novel synthetic drugs on human breast carcinoma MCF-7 cells.

  2009cited by this paper
• Quantitative protein expression profiling of 14‐3‐3 isoforms in human renal carcinoma shows 14‐3‐3 epsilon is involved in limitedly increasing renal cell proliferation

  2009cited by this paper
• Isoform-specific expression of 14-3-3 proteins in human astrocytoma.

  2009cited by this paper
• Isoform‐specific expression and characterization of 14‐3‐3 proteins in human glioma tissues discovered by stable isotope labeling with amino acids in cell culture‐based proteomic analysis

  2009cited by this paper
• Characterization of early stages of human B cell development by gene expression profiling

  2009cited by this paper
• The cancer secretome: a reservoir of biomarkers

  2008cited by this paper
• Preclinical Toxicity, Toxicokinetics, and Antitumoral Efficacy Studies of DTS-201, a Tumor-Selective Peptidic Prodrug of Doxorubicin

  2008cited by this paper
• Characterization of thimet oligopeptidase and neurolysin activities in B16F10-Nex2 tumor cells and their involvement in angiogenesis and tumor growth

  2007cited by this paper
• Characterization of Early Stages of Human B Cell Development by Gene Expression Profiling1

  2007cited by this paper
• Thimet oligopeptidase (EC 3.4.24.15) activates CPI-0004Na, an extracellularly tumour-activated prodrug of doxorubicin.

  2006influential reference
• Immunophenotyping of acute leukaemias.

  2005cited by this paper
• Isoform‐specific expression of 14‐3‐3 proteins in human lung cancer tissues

  2005cited by this paper
• 14‐3‐3 epsilon modulates the stimulated secretion of endopeptidase 24.15

  2005cited by this paper
• The intracellular distribution and secretion of endopeptidases 24.15 (EC 3.4.24.15) and 24.16 (EC 3.4.24.16).

  2004cited by this paper
• CD10 is a key enzyme involved in the activation of tumor-activated peptide prodrug CPI-0004Na and novel analogues: implications for the design of novel peptide prodrugs for the therapy of CD10+ tumors.

  2003influential reference
• CPI-0004Na, a new extracellularly tumor-activated prodrug of doxorubicin: in vivo toxicity, activity, and tissue distribution confirm tumor cell selectivity.

  2002influential reference
• The Neuropeptide Processing Enzyme EC 3.4.24.15 Is Modulated by Protein Kinase A Phosphorylation*

  2000cited by this paper
• The role of proteolytic enzymes in cancer invasion and metastasis

  1992cited by this paper
• A direct measurement of the radiation sensitivity of normal mouse bone marrow cells.

  1961influential reference

• New conjugates of natural chlorins with doxorubicin featuring controlled release for combined photodynamic and chemotherapeutic treatment.

  2026cites this paper
• Drastic Impact of Donor Substituents on Xanthenes in the PDT of Glioblastoma

  2025cites this paper
• Prodrugs as empowering tools in drug discovery and development: recent strategic applications of drug delivery solutions to mitigate challenges associated with lead compounds and drug candidates.

  2024cites this paper
• From basic research to clinical application: targeting fibroblast activation protein for cancer diagnosis and treatment

  2023cites this paper
• Enhanced Antitumor Efficacy of PhAc-ALGP-Dox, an Enzyme-Activated Doxorubicin Prodrug, in a Panel of THOP1-Expressing Patient-Derived Xenografts of Soft Tissue Sarcoma

  2022cites this paper
• Peptide–drug conjugates (PDCs): a novel trend of research and development on targeted therapy, hype or hope?

  2022cites this paper